Company intelligence / Profile preview

Handa Therapeutics

Lewes, Delaware, United States

Ownership: Private
Development stage: Other

Overview

Handa Therapeutics has acquired PHYRAGO™ (dasatinib), an FDA-approved drug for Ph+ CML and Ph+ ALL. PHYRAGO™ is the first dasatinib formulation compatible with gastric acid-reducing agents, and secured orphan-drug status with exclusive marketing rights until at least 2026, possibly 2030 if full Orphan Drug Exclusivity is granted[3].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Handa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Handa Therapeutics.

Explore the full profile